BNTC Benitec Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BNTC

Price (delayed)

$9.83

Market cap

$342.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.98

Enterprise value

$163.52M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” ...

Highlights
The debt has contracted by 13% from the previous quarter and by 10% YoY
The equity has soared by 82% YoY but it has contracted by 3.4% from the previous quarter
The company's EPS rose by 7% YoY but it fell by 5% QoQ
The company's quick ratio fell by 40% QoQ and by 38% YoY
BNTC's net income is down by 20% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.benitec.com
Peers: NTLA CRSP EDIT QURE

Key stats

What are the main financial stats of BNTC

BNTC stock price

How has the Benitec Biopharma stock price performed over time
Intraday
-10.23%
1 week
-10.96%
1 month
-27.08%
1 year
-25.64%
YTD
-27.02%
QTD
-26.53%

Financial performance

How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.19M
Net income
-$45.55M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 23% year-on-year and by 10% since the previous quarter
BNTC's net income is down by 20% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does BNTC's price correlate with its fundamentals

Growth

What is Benitec Biopharma's growth rate over time

Valuation

What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 7% YoY but it fell by 5% QoQ
The equity has soared by 82% YoY but it has contracted by 3.4% from the previous quarter
BNTC's P/B is 39% below its 5-year quarterly average of 3.5 and 21% below its last 4 quarters average of 2.7

Efficiency

How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has increased by 37% YoY and by 4.1% QoQ
Benitec Biopharma's ROA has increased by 35% YoY and by 4.1% from the previous quarter

Dividends

What is BNTC's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Benitec Biopharma financials performed over time
Benitec Biopharma's total liabilities has soared by 144% YoY and by 53% from the previous quarter
The company's total assets has surged by 83% YoY but it fell by 2.3% QoQ
The debt is 100% less than the equity
The debt to equity has plunged by 100% YoY
The equity has soared by 82% YoY but it has contracted by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.